Cross-Sector entity
Of the tracked stories, 2 of 2 also mention Cannabis Hyperemesis Syndrome, the most common co-covered peer. clinical-trial accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each carries 2 original sources on average.
2 verified stories tracked
Last mentioned: Aug 7, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention Cannabis Hyperemesis Syndrome, the most common co-covered peer. clinical-trial accounts for 1 of the 2 tracked stories, while 1 other category carries the remainder. Each carries 2 original sources on average. We currently track 2 Cross-Sector stories that mention CDC National Center for Injury Prevention and Control, all published on August 7, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CDC National Center for Injury Prevention and Control. Shared-story counts are live from our verified record — not editorial picks.
The introduction of a dedicated ICD-10 code for cannabis hyperemesis syndrome triggered a 16% jump in emergency department diagnoses, unmasking a massive hidden burden on U.S. hospitals. With 200,000 prior ED visits and 2.75 million annual sufferers, health systems must now manage increased demand, train clinicians, and integrate the new code into EHRs and population health analytics.
With 2.75 million suffering from cannabis hyperemesis syndrome and a 16% jump in ED diagnoses after a new ICD code, an underserved patient population emerges. Biopharma companies can explore targeted therapies for CHS, a condition currently managed only with abstinence and supportive care, presenting a significant unmet medical need.
Source: troyrecord.com · MedPage Today
